We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it's five. And once again, regulatory delays are part of the problem.